摘要
目的研究不同剂量缬沙坦治疗慢性心力衰竭(Chronic heart failure,CHF)的疗效。方法将94例CHF患者随机分为A、B、C三组,在常规治疗后分别给予80 mg/d、160 mg/d、320 mg/d的缬沙坦,治疗4周、12周后观察治疗效果。结果 B、C组4周、12周后脑钠肽(BNP)、左室射血分数(LVEF)、左室舒张末期容积指数(LVEDVI)、总有效率与A组比较,有统计学意义(均P<0.05);B组、C组4周后BNP、LVEF、LVEDVI、总有效率比较无统计学意义(均P>0.05),12周后C组LVEF高于B组(P<0.05);A、B组不良反应发生率低于C组(P<0.05)。结论 160mg/d缬沙坦治疗CHF可提高患者LVEF,改善心功能,不良反应少。
Objective To understand the effect of valsartan when prepared in different doses for the treatment of chronic heart failure （CHF）. Method 94 subjects were randomly divided into three groups, group A, group B and group C. All groups were firstly treated with conventional treatment and then were given valsartan of 80mg/d once, 160mg/d 2 times, 360mg/d 2 times respectively. The effects of the different doses were examined 4 weeks after and 12 weeks after treatment. Findings The BNP, LVEF, LVEDVI and the total efficiency of group B and group C as observed 4 weeks after and 12 weeks after treatment as compared to those of group were statistically significant （P 〈 0.05）. The BNP, LVEF, LVEDV between group B and group C showed no significant difference 4 weeks after treatment （P 〉 0.05）. The LVEF of group C was higher than that of group B 12 weeks after treatment （ P 〈 0.05 ）. The incidence rate of adverse reaction of group A and group B were lower than that of group C （P 〈 0.05 ）. Conclusion 160mg/d of valsartan for patients with CHF was found to be able to improve LVEF arid heart function and reduce adverse reaction.
出处
《健康研究》
CAS
2015年第1期28-29,32,共3页
Health Research
关键词
慢性心力衰竭
缬沙坦
剂量
心功能
chronic heart failure
valsartan
dose
cardiac function
